Researchers sought to see how oxytocin versus, sublingual misoprostol affected estimated and measured blood loss during vaginal delivery in women who had blood loss >300 ml .

The greatest cause of maternal mortality globally is postpartum hemorrhage (PPH), which is defined as a blood loss of 500 mL or more after birth. All women giving birth should be given a preventive uterotonic drug, according to the World Health Organization (WHO).

Despite the use of a uterotonic drug as a preventative measure, PPH remains a frequent complication, accounting for one-quarter of all maternal fatalities worldwide. When prophylaxis fails and PPH develops, it is advised that uterotonic medicines be used as first-line therapy. However, it's unclear whether the uterotonic drug is better for treating PPH as first-line therapy.

Inclusion Criteria:

• vaginal birth in women who had blood loss >300 ml

Exclusion Criteria:

• <37 weeks of pregnancy,
• genital tract injuries,
• coagulation deficit,
• hypertension, preeclampsia,
• cardiac, renal, or hepatic disease,
• epilepsy,

vaginal birth in women who had blood loss >300 ml

double-blinded a randomized controlled trial